Cargando…
P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI
| Autores principales: | , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171816/ http://dx.doi.org/10.1097/01.HS9.0000936264.13828.1f |
| _version_ | 1785039504253386752 |
|---|---|
| author | Mateos, M Szarejko, M Bila, J Schjesvold, F Spicka, I Maisnar, V Jurczyszyn, A Grudeva-Popova, Z Hajek, R Usenko, G Thuresson, M Norin, S Jarefors, S Richardson, P Pour, L |
| author_facet | Mateos, M Szarejko, M Bila, J Schjesvold, F Spicka, I Maisnar, V Jurczyszyn, A Grudeva-Popova, Z Hajek, R Usenko, G Thuresson, M Norin, S Jarefors, S Richardson, P Pour, L |
| author_sort | Mateos, M |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10171816 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-101718162023-05-11 P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI Mateos, M Szarejko, M Bila, J Schjesvold, F Spicka, I Maisnar, V Jurczyszyn, A Grudeva-Popova, Z Hajek, R Usenko, G Thuresson, M Norin, S Jarefors, S Richardson, P Pour, L Hemasphere Poster Lippincott Williams & Wilkins 2023-05-09 /pmc/articles/PMC10171816/ http://dx.doi.org/10.1097/01.HS9.0000936264.13828.1f Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Poster Mateos, M Szarejko, M Bila, J Schjesvold, F Spicka, I Maisnar, V Jurczyszyn, A Grudeva-Popova, Z Hajek, R Usenko, G Thuresson, M Norin, S Jarefors, S Richardson, P Pour, L P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI |
| title | P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI |
| title_full | P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI |
| title_fullStr | P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI |
| title_full_unstemmed | P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI |
| title_short | P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI |
| title_sort | p34 lighthouse (op-108): melflufen plus daratumumab (dara) and dexamethasone (dex) versus dara in relapsed/refractory multiple myeloma (rrmm) refractory to an immunomodulatory drug (imid) and a proteasome inhibitor (pi) or had received ≥3 prior lines of therapy including an imid and a pi |
| topic | Poster |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10171816/ http://dx.doi.org/10.1097/01.HS9.0000936264.13828.1f |
| work_keys_str_mv | AT mateosm p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT szarejkom p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT bilaj p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT schjesvoldf p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT spickai p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT maisnarv p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT jurczyszyna p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT grudevapopovaz p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT hajekr p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT usenkog p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT thuressonm p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT norins p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT jareforss p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT richardsonp p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi AT pourl p34lighthouseop108melflufenplusdaratumumabdaraanddexamethasonedexversusdarainrelapsedrefractorymultiplemyelomarrmmrefractorytoanimmunomodulatorydrugimidandaproteasomeinhibitorpiorhadreceived3priorlinesoftherapyincludinganimidandapi |